25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Komipharm International Co. Ltd
Buy, Hold or Sell?

Let's analyze Komipharm together

I guess you are interested in Komipharm International Co. Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Komipharm International Co. Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Komipharm International Co. Ltd

I send you an email if I find something interesting about Komipharm International Co. Ltd.

1. Quick Overview

1.1. Quick analysis of Komipharm (30 sec.)










1.2. What can you expect buying and holding a share of Komipharm? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩918.12
Expected worth in 1 year
₩991.18
How sure are you?
52.5%

+ What do you gain per year?

Total Gains per Share
₩73.06
Return On Investment
1.9%

For what price can you sell your share?

Current Price per Share
₩3,940.00
Expected price per share
₩3,735 - ₩4,445
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Komipharm (5 min.)




Live pricePrice per Share (EOD)
₩3,940.00

2.2. Growth of Komipharm (5 min.)




Is Komipharm growing?

Current yearPrevious yearGrowGrow %
How rich?$44.6m$43.5m-$580.5k-1.4%

How much money is Komipharm making?

Current yearPrevious yearGrowGrow %
Making money$600.8k-$1.5m$2.1m364.3%
Net Profit Margin1.4%-22.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Komipharm (5 min.)




2.4. Comparing to competitors in the Pharmaceuticals industry (5 min.)




  Industry Rankings (Pharmaceuticals)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Komipharm?

Welcome investor! Komipharm's management wants to use your money to grow the business. In return you get a share of Komipharm.

First you should know what it really means to hold a share of Komipharm. And how you can make/lose money.

Speculation

The Price per Share of Komipharm is ₩3,940. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Komipharm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Komipharm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩918.12. Based on the TTM, the Book Value Change Per Share is ₩18.27 per quarter. Based on the YOY, the Book Value Change Per Share is ₩-55.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Komipharm.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.050.0%0.010.0%-0.020.0%-0.020.0%-0.010.0%
Usd Book Value Change Per Share0.040.0%0.010.0%-0.040.0%-0.020.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.040.0%0.010.0%-0.040.0%-0.020.0%0.000.0%
Usd Price Per Share2.89-3.23-4.85-7.05-13.57-
Price to Earnings Ratio14.08--5.93--113.63--146.98-1,981.57-
Price-to-Total Gains Ratio74.47-165.80--402.42--8.20--347.20-
Price to Book Ratio4.50-5.27-7.83-9.16-22.91-
Price-to-Total Gains Ratio74.47-165.80--402.42--8.20--347.20-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.758
Number of shares362
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.01-0.02
Usd Total Gains Per Share0.01-0.02
Gains per Quarter (362 shares)4.63-8.17
Gains per Year (362 shares)18.51-32.70
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101990-33-43
2037280-65-76
3056470-98-109
4074660-131-142
5093850-163-175
601111040-196-208
701301230-229-241
801481420-262-274
901671610-294-307
1001851800-327-340

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%3.09.00.025.0%5.015.00.025.0%11.022.07.027.5%14.022.010.030.4%
Book Value Change Per Share3.01.00.075.0%5.07.00.041.7%8.012.00.040.0%21.019.00.052.5%25.021.00.054.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.046.00.0%
Total Gains per Share3.01.00.075.0%5.07.00.041.7%8.012.00.040.0%21.019.00.052.5%25.021.00.054.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Komipharm International Co. Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--55.45818.266+204%-55.152+199%-32.257+158%2.724+1936%
Book Value Per Share--918.117877.078+5%885.973+4%1063.382-14%1217.953-25%
Current Ratio--1.1631.132+3%1.048+11%1.307-11%1.012+15%
Debt To Asset Ratio--0.4820.492-2%0.456+6%0.422+14%0.397+22%
Debt To Equity Ratio--0.9841.032-5%0.844+17%0.757+30%0.706+39%
Dividend Per Share----0%-0%-0%-0%
Eps--73.33112.425+490%-32.329+144%-25.512+135%-19.677+127%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.825+21%
Market Cap227778886000.000-26%286745251590.000322922413325.000-11%485926741691.838-41%656286267102.145-56%2067037861296.952-86%
Net Profit Margin--0.2660.014+1771%-0.223+184%-0.183+169%-0.140+153%
Operating Margin----0%-0.0560%-0.0840%-0.0620%
Operating Ratio--1.1071.650-33%1.341-17%1.128-2%1.140-3%
Pb Ratio4.291-5%4.4985.269-15%7.834-43%9.164-51%22.907-80%
Pe Ratio13.432-5%14.080-5.933+142%-113.631+907%-146.978+1144%1981.568-99%
Price Per Share3940.000-5%4130.0004613.750-10%6922.502-40%10077.252-59%19389.882-79%
Price To Free Cash Flow Ratio----75.9010%65.686-100%-306.0360%321.983-100%
Price To Total Gains Ratio71.045-5%74.471165.798-55%-402.424+640%-8.196+111%-347.203+566%
Quick Ratio---0.195-100%0.596-100%0.789-100%0.621-100%
Return On Assets--0.0410.007+484%-0.020+149%-0.014+133%-0.010+124%
Return On Equity--0.0850.014+509%-0.037+144%-0.023+128%-0.016+119%
Total Gains Per Share--55.45818.266+204%-55.152+199%-32.257+158%2.724+1936%
Usd Book Value--44621306.80042954648.301+4%43535195.853+2%48965356.115-9%55101935.468-19%
Usd Book Value Change Per Share--0.0390.013+204%-0.039+199%-0.023+158%0.002+1936%
Usd Book Value Per Share--0.6430.614+5%0.620+4%0.744-14%0.853-25%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0510.009+490%-0.023+144%-0.018+135%-0.014+127%
Usd Free Cash Flow----830376.1940%-100066.7730%-865797.9810%-1043856.8040%
Usd Market Cap159445220.200-26%200721676.113226045689.328-11%340148719.184-41%459400386.972-56%1446926502.908-86%
Usd Price Per Share2.758-5%2.8913.230-10%4.846-40%7.054-59%13.573-79%
Usd Profit--3563964.600600848.861+493%-1588168.164+145%-1156783.771+132%-887558.507+125%
Usd Revenue--13407440.2008991230.679+49%7303805.203+84%7197733.276+86%6777664.256+98%
Usd Total Gains Per Share--0.0390.013+204%-0.039+199%-0.023+158%0.002+1936%
 EOD+3 -4MRQTTM+20 -6YOY+20 -75Y+15 -1110Y+19 -9

3.3 Fundamental Score

Let's check the fundamental score of Komipharm International Co. Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1513.432
Price to Book Ratio (EOD)Between0-14.291
Net Profit Margin (MRQ)Greater than00.266
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than11.163
Debt to Asset Ratio (MRQ)Less than10.482
Debt to Equity Ratio (MRQ)Less than10.984
Return on Equity (MRQ)Greater than0.150.085
Return on Assets (MRQ)Greater than0.050.041
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Komipharm International Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.404
Ma 20Greater thanMa 504,142.000
Ma 50Greater thanMa 1004,135.200
Ma 100Greater thanMa 2004,120.050
OpenGreater thanClose3,975.000
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Komipharm International Co. Ltd

Komipharm International Co., Ltd. manufactures and sells veterinary vaccines, veterinary pharmaceuticals and disinfectants, and bio-fertilizers internationally. It also develops anticancer drugs and pain-relieving agents, which include Kominox, an arsenic-based oral drug; and Panaphix, a non-narcotic cancer pain reliever, as well as provides clinical pathological experiment, test, and analysis services. The company was formerly known as Korea Microbiological Laboratories Co., Ltd. and changed its name to Komipharm International Co., Ltd. in September 2004. The company was founded in 1972 and is headquartered in Siheung, South Korea.

Fundamental data was last updated by Penke on 2024-11-18 14:10:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Komipharm earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Komipharm to the Pharmaceuticals industry mean.
  • A Net Profit Margin of 26.6% means that ₩0.27 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Komipharm International Co. Ltd:

  • The MRQ is 26.6%. The company is making a huge profit. +2
  • The TTM is 1.4%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ26.6%TTM1.4%+25.2%
TTM1.4%YOY-22.3%+23.7%
TTM1.4%5Y-18.3%+19.7%
5Y-18.3%10Y-14.0%-4.3%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ26.6%9.8%+16.8%
TTM1.4%9.5%-8.1%
YOY-22.3%9.9%-32.2%
5Y-18.3%12.9%-31.2%
10Y-14.0%12.6%-26.6%
4.3.1.2. Return on Assets

Shows how efficient Komipharm is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Komipharm to the Pharmaceuticals industry mean.
  • 4.1% Return on Assets means that Komipharm generated ₩0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Komipharm International Co. Ltd:

  • The MRQ is 4.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is 0.7%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ4.1%TTM0.7%+3.4%
TTM0.7%YOY-2.0%+2.7%
TTM0.7%5Y-1.4%+2.1%
5Y-1.4%10Y-1.0%-0.4%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1%3.6%+0.5%
TTM0.7%3.5%-2.8%
YOY-2.0%5.3%-7.3%
5Y-1.4%5.9%-7.3%
10Y-1.0%4.9%-5.9%
4.3.1.3. Return on Equity

Shows how efficient Komipharm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Komipharm to the Pharmaceuticals industry mean.
  • 8.5% Return on Equity means Komipharm generated ₩0.08 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Komipharm International Co. Ltd:

  • The MRQ is 8.5%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 1.4%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ8.5%TTM1.4%+7.1%
TTM1.4%YOY-3.7%+5.1%
TTM1.4%5Y-2.3%+3.7%
5Y-2.3%10Y-1.6%-0.7%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ8.5%4.6%+3.9%
TTM1.4%4.6%-3.2%
YOY-3.7%8.2%-11.9%
5Y-2.3%9.1%-11.4%
10Y-1.6%10.3%-11.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Komipharm International Co. Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Komipharm is operating .

  • Measures how much profit Komipharm makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Komipharm to the Pharmaceuticals industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Komipharm International Co. Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-5.6%+5.6%
TTM-5Y-8.4%+8.4%
5Y-8.4%10Y-6.2%-2.2%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.2%-13.2%
TTM-12.0%-12.0%
YOY-5.6%12.4%-18.0%
5Y-8.4%8.6%-17.0%
10Y-6.2%12.1%-18.3%
4.3.2.2. Operating Ratio

Measures how efficient Komipharm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • An Operation Ratio of 1.11 means that the operating costs are ₩1.11 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Komipharm International Co. Ltd:

  • The MRQ is 1.107. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.650. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.107TTM1.650-0.542
TTM1.650YOY1.341+0.308
TTM1.6505Y1.128+0.522
5Y1.12810Y1.140-0.012
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1071.225-0.118
TTM1.6501.220+0.430
YOY1.3411.311+0.030
5Y1.1281.249-0.121
10Y1.1401.240-0.100
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Komipharm International Co. Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Komipharm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A Current Ratio of 1.16 means the company has ₩1.16 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Komipharm International Co. Ltd:

  • The MRQ is 1.163. The company is just able to pay all its short-term debts.
  • The TTM is 1.132. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.163TTM1.132+0.032
TTM1.132YOY1.048+0.084
TTM1.1325Y1.307-0.176
5Y1.30710Y1.012+0.295
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1632.213-1.050
TTM1.1322.234-1.102
YOY1.0482.028-0.980
5Y1.3072.199-0.892
10Y1.0121.995-0.983
4.4.3.2. Quick Ratio

Measures if Komipharm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Komipharm to the Pharmaceuticals industry mean.
  • A Quick Ratio of 0.00 means the company can pay off ₩0.00 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Komipharm International Co. Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.195-0.195
TTM0.195YOY0.596-0.400
TTM0.1955Y0.789-0.593
5Y0.78910Y0.621+0.168
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.926-0.926
TTM0.1950.973-0.778
YOY0.5961.515-0.919
5Y0.7891.591-0.802
10Y0.6211.399-0.778
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Komipharm International Co. Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Komipharm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Komipharm to Pharmaceuticals industry mean.
  • A Debt to Asset Ratio of 0.48 means that Komipharm assets are financed with 48.2% credit (debt) and the remaining percentage (100% - 48.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Komipharm International Co. Ltd:

  • The MRQ is 0.482. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.492. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.482TTM0.492-0.010
TTM0.492YOY0.456+0.036
TTM0.4925Y0.422+0.070
5Y0.42210Y0.397+0.026
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4820.345+0.137
TTM0.4920.339+0.153
YOY0.4560.333+0.123
5Y0.4220.315+0.107
10Y0.3970.339+0.058
4.5.4.2. Debt to Equity Ratio

Measures if Komipharm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Komipharm to the Pharmaceuticals industry mean.
  • A Debt to Equity ratio of 98.4% means that company has ₩0.98 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Komipharm International Co. Ltd:

  • The MRQ is 0.984. The company is very able to pay all its debts with equity. +2
  • The TTM is 1.032. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ0.984TTM1.032-0.048
TTM1.032YOY0.844+0.188
TTM1.0325Y0.757+0.275
5Y0.75710Y0.706+0.051
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9840.547+0.437
TTM1.0320.547+0.485
YOY0.8440.499+0.345
5Y0.7570.476+0.281
10Y0.7060.548+0.158
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Komipharm generates.

  • Above 15 is considered overpriced but always compare Komipharm to the Pharmaceuticals industry mean.
  • A PE ratio of 14.08 means the investor is paying ₩14.08 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Komipharm International Co. Ltd:

  • The EOD is 13.432. Based on the earnings, the company is underpriced. +1
  • The MRQ is 14.080. Based on the earnings, the company is underpriced. +1
  • The TTM is -5.933. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD13.432MRQ14.080-0.648
MRQ14.080TTM-5.933+20.013
TTM-5.933YOY-113.631+107.698
TTM-5.9335Y-146.978+141.045
5Y-146.97810Y1,981.568-2,128.546
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD13.43227.863-14.431
MRQ14.08029.844-15.764
TTM-5.93327.532-33.465
YOY-113.63123.102-136.733
5Y-146.97827.577-174.555
10Y1,981.56829.248+1,952.320
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Komipharm International Co. Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-75.901+75.901
TTM-75.901YOY65.686-141.586
TTM-75.9015Y-306.036+230.136
5Y-306.03610Y321.983-628.019
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.531-29.531
TTM-75.90129.447-105.348
YOY65.68626.360+39.326
5Y-306.03631.734-337.770
10Y321.98334.357+287.626
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Komipharm is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A PB ratio of 4.50 means the investor is paying ₩4.50 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Komipharm International Co. Ltd:

  • The EOD is 4.291. Based on the equity, the company is fair priced.
  • The MRQ is 4.498. Based on the equity, the company is fair priced.
  • The TTM is 5.269. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.291MRQ4.498-0.207
MRQ4.498TTM5.269-0.770
TTM5.269YOY7.834-2.565
TTM5.2695Y9.164-3.896
5Y9.16410Y22.907-13.742
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD4.2914.659-0.368
MRQ4.4983.381+1.117
TTM5.2693.209+2.060
YOY7.8342.597+5.237
5Y9.1643.278+5.886
10Y22.9074.179+18.728
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets123,043,990
Total Liabilities59,299,266
Total Stockholder Equity60,246,651
 As reported
Total Liabilities 59,299,266
Total Stockholder Equity+ 60,246,651
Total Assets = 123,043,990

Assets

Total Assets123,043,990
Total Current Assets59,596,137
Long-term Assets63,447,853
Total Current Assets
Total Current Assets  (as reported)59,596,137
Total Current Assets  (calculated)0
+/- 59,596,137
Long-term Assets
Long-term Assets  (as reported)63,447,853
Long-term Assets  (calculated)0
+/- 63,447,853

Liabilities & Shareholders' Equity

Total Current Liabilities51,221,592
Long-term Liabilities8,077,673
Total Stockholder Equity60,246,651
Total Current Liabilities
Total Current Liabilities  (as reported)51,221,592
Total Current Liabilities  (calculated)0
+/- 51,221,592
Long-term Liabilities
Long-term Liabilities  (as reported)8,077,673
Long-term Liabilities  (calculated)0
+/- 8,077,673
Total Stockholder Equity
Total Stockholder Equity (as reported)60,246,651
Total Stockholder Equity (calculated)0
+/- 60,246,651
Other
Common Stock Shares Outstanding 69,430
Net Invested Capital 60,246,651
Net Working Capital 8,374,545



6.2. Balance Sheets Structured

Currency in KRW. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
83,244,204
94,275,588
109,746,206
108,796,731
111,447,063
114,572,387
116,422,471
124,397,607
116,450,170
123,819,451
119,788,199
133,389,118
131,559,655
133,483,261
131,445,000
149,843,271
153,258,089
152,792,818
149,755,089
149,268,453
145,417,495
150,183,035
140,791,517
139,903,685
138,976,247
149,539,668
147,006,466
125,644,473
122,532,418
125,281,583
123,816,100
121,912,528
118,425,005
120,596,181
116,999,459
115,261,543
119,118,396
118,806,726
116,953,604
111,750,977
113,758,618
114,989,039
126,682,104
118,597,807
115,640,529
123,043,990
123,043,990115,640,529118,597,807126,682,104114,989,039113,758,618111,750,977116,953,604118,806,726119,118,396115,261,543116,999,459120,596,181118,425,005121,912,528123,816,100125,281,583122,532,418125,644,473147,006,466149,539,668138,976,247139,903,685140,791,517150,183,035145,417,495149,268,453149,755,089152,792,818153,258,089149,843,271131,445,000133,483,261131,559,655133,389,118119,788,199123,819,451116,450,170124,397,607116,422,471114,572,387111,447,063108,796,731109,746,20694,275,58883,244,204
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
54,562,780
49,528,968
53,634,097
46,572,370
48,581,947
39,728,372
48,743,115
47,187,807
52,451,373
49,835,903
46,909,364
45,178,274
47,323,958
46,374,860
44,674,937
40,861,585
46,194,986
42,801,741
41,452,146
44,924,256
45,462,909
43,212,881
42,628,668
44,683,854
45,866,042
58,319,510
50,011,513
51,447,624
59,596,137
59,596,13751,447,62450,011,51358,319,51045,866,04244,683,85442,628,66843,212,88145,462,90944,924,25641,452,14642,801,74146,194,98640,861,58544,674,93746,374,86047,323,95845,178,27446,909,36449,835,90352,451,37347,187,80748,743,11539,728,37248,581,94746,572,37053,634,09749,528,96854,562,78000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,768,271
22,001,495
27,585,383
17,884,883
16,051,855
12,194,342
19,173,826
15,822,219
23,092,398
18,969,005
18,874,461
15,957,937
18,412,996
14,833,234
15,046,197
13,419,175
14,982,037
12,558,650
2,081
2,078
1,600
2,162
1,438
933
408
24,876,766
14,819,531
10,185,694
0
010,185,69414,819,53124,876,7664089331,4382,1621,6002,0782,08112,558,65014,982,03713,419,17515,046,19714,833,23418,412,99615,957,93718,874,46118,969,00523,092,39815,822,21919,173,82612,194,34216,051,85517,884,88327,585,38322,001,49526,768,27100000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,027,245
1,000,000
0
0
0
0
3,013,095
3,027,359
3,042,831
2,037,677
2,045,937
0
0
4,055,147
2,057,309
0
4,915,719
4,944,710
1,937,077
1,938,200
1,939,323
1,914,000
0
1,000,000
0
0
0
0
0
000001,000,00001,914,0001,939,3231,938,2001,937,0774,944,7104,915,71902,057,3094,055,147002,045,9372,037,6773,042,8313,027,3593,013,09500001,000,0001,027,24500000000000000000
       Net Receivables 
12,499,001
10,994,640
11,952,757
13,850,903
14,215,193
13,374,813
13,204,550
15,301,071
13,595,619
13,604,263
12,513,608
13,591,208
12,808,955
13,172,022
12,428,765
12,720,760
12,976,963
14,270,720
13,713,350
12,933,410
12,850,944
12,357,863
12,503,860
12,772,801
12,309,181
12,206,544
11,353,171
12,988,379
13,631,563
13,776,383
13,573,844
12,962,681
12,651,521
12,284,004
11,354,923
12,848,002
16,380,825
16,358,985
15,125,316
10,849,000
12,099,971
12,275,980
12,008,331
12,041,533
13,299,327
0
013,299,32712,041,53312,008,33112,275,98012,099,97110,849,00015,125,31616,358,98516,380,82512,848,00211,354,92312,284,00412,651,52112,962,68113,573,84413,776,38313,631,56312,988,37911,353,17112,206,54412,309,18112,772,80112,503,86012,357,86312,850,94412,933,41013,713,35014,270,72012,976,96312,720,76012,428,76513,172,02212,808,95513,591,20812,513,60813,604,26313,595,61915,301,07113,204,55013,374,81314,215,19313,850,90311,952,75710,994,64012,499,001
       Other Current Assets 
5,153,509
6,096,265
5,135,695
4,089,397
4,336,456
335,423
563,032
528,385
513,287
323,035
509,789
585,164
493,189
1,013,472
555,114
457,278
723,342
576,104
444,858
1,206,742
1,493,277
511,939
629,528
381,928
599,996
454,157
119,941
368,700
518,040
369,540
514,273
624,054
341,707
181,332
234,270
315,900
275,660
241,684
572,123
1,085,708
49,533
41,214
31,414
30,861
33,210
0
033,21030,86131,41441,21449,5331,085,708572,123241,684275,660315,900234,270181,332341,707624,054514,273369,540518,040368,700119,941454,157599,996381,928629,528511,9391,493,2771,206,742444,858576,104723,342457,278555,1141,013,472493,189585,164509,789323,035513,287528,385563,032335,4234,336,4564,089,3975,135,6956,096,2655,153,509
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
69,122,309
69,074,764
69,122,997
68,362,593
68,586,294
64,192,904
63,447,853
63,447,85364,192,90468,586,29468,362,59369,122,99769,074,76469,122,309000000000000000000000000000000000000000
       Property Plant Equipment 
33,747,279
44,024,294
54,278,364
55,024,060
55,487,796
60,189,507
62,451,734
61,153,400
61,807,951
62,487,367
63,425,024
66,101,462
73,109,752
72,296,165
71,957,919
71,975,256
71,371,215
71,312,294
71,984,264
70,327,743
71,261,518
72,672,711
71,716,784
71,714,642
71,542,225
74,619,326
73,957,491
73,701,791
72,321,938
72,998,830
72,230,726
72,063,154
72,011,966
71,211,140
70,511,496
70,140,787
70,458,593
69,609,623
69,975,644
66,522,021
66,344,788
65,486,584
64,702,370
64,239,222
57,819,498
0
057,819,49864,239,22264,702,37065,486,58466,344,78866,522,02169,975,64469,609,62370,458,59370,140,78770,511,49671,211,14072,011,96672,063,15472,230,72672,998,83072,321,93873,701,79173,957,49174,619,32671,542,22571,714,64271,716,78472,672,71171,261,51870,327,74371,984,26471,312,29471,371,21571,975,25671,957,91972,296,16573,109,75266,101,46263,425,02462,487,36761,807,95161,153,40062,451,73460,189,50755,487,79655,024,06054,278,36444,024,29433,747,279
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,048,607
2,084,389
6,413,061
8,138,259
10,034,361
9,598,651
7,223,208
7,685,519
7,677,206
7,574,295
3,942,677
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000003,942,6777,574,2957,677,2067,685,5197,223,2089,598,65110,034,3618,138,2596,413,0612,084,3892,048,60700000000000000000
       Intangible Assets 
306,922
303,144
302,065
330,279
328,414
250,369
246,376
4,894,828
4,970,640
5,068,607
5,209,978
4,462,264
4,638,143
4,536,582
4,628,734
4,050,486
4,096,924
4,235,461
4,231,449
65,993
62,122
85,669
81,361
62,488
68,383
2,280,470
6,604,403
827,401
799,234
775,163
747,800
685,340
650,491
658,345
928,615
909,267
978,428
975,356
975,381
808,223
935,437
990,327
1,082,057
1,214,135
3,266,190
0
03,266,1901,214,1351,082,057990,327935,437808,223975,381975,356978,428909,267928,615658,345650,491685,340747,800775,163799,234827,4016,604,4032,280,47068,38362,48881,36185,66962,12265,9934,231,4494,235,4614,096,9244,050,4864,628,7344,536,5824,638,1434,462,2645,209,9785,068,6074,970,6404,894,828246,376250,369328,414330,279302,065303,144306,922
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
0
1
1
-1
0
0-11100-1000000000000000000000000000000000000000
> Total Liabilities 
38,407,092
49,203,326
64,608,523
64,076,821
66,749,275
67,794,156
69,018,700
71,238,938
63,620,808
49,718,171
47,638,813
57,259,368
53,710,535
54,277,589
51,285,246
50,542,294
54,085,854
52,888,296
47,566,299
41,964,048
34,899,744
37,603,301
30,163,790
41,916,874
41,243,155
50,170,624
52,946,554
52,368,861
47,478,215
46,069,247
45,646,941
45,637,116
41,028,993
44,640,580
43,445,458
48,801,420
51,830,711
50,724,291
48,181,158
51,120,255
53,682,594
55,695,685
65,504,878
58,582,669
55,122,483
59,299,266
59,299,26655,122,48358,582,66965,504,87855,695,68553,682,59451,120,25548,181,15850,724,29151,830,71148,801,42043,445,45844,640,58041,028,99345,637,11645,646,94146,069,24747,478,21552,368,86152,946,55450,170,62441,243,15541,916,87430,163,79037,603,30134,899,74441,964,04847,566,29952,888,29654,085,85450,542,29451,285,24654,277,58953,710,53557,259,36847,638,81349,718,17163,620,80871,238,93869,018,70067,794,15666,749,27564,076,82164,608,52349,203,32638,407,092
   > Total Current Liabilities 
12,280,191
22,708,980
23,131,564
33,025,741
45,834,443
45,274,945
49,068,231
38,053,689
26,112,453
25,009,886
25,238,593
26,922,370
24,965,300
27,616,833
25,652,831
36,928,569
34,414,186
35,778,094
41,403,024
36,106,669
29,490,636
23,856,758
16,662,849
37,936,024
36,885,945
33,381,964
31,810,003
31,034,929
26,399,098
37,812,850
37,461,976
39,337,579
34,931,018
25,999,692
25,006,894
25,684,609
28,220,163
39,628,986
38,686,743
41,047,474
43,986,381
44,933,061
43,155,129
52,228,262
48,808,700
51,221,592
51,221,59248,808,70052,228,26243,155,12944,933,06143,986,38141,047,47438,686,74339,628,98628,220,16325,684,60925,006,89425,999,69234,931,01839,337,57937,461,97637,812,85026,399,09831,034,92931,810,00333,381,96436,885,94537,936,02416,662,84923,856,75829,490,63636,106,66941,403,02435,778,09434,414,18636,928,56925,652,83127,616,83324,965,30026,922,37025,238,59325,009,88626,112,45338,053,68949,068,23145,274,94545,834,44333,025,74123,131,56422,708,98012,280,191
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48,066,418
25,991,710
17,837,779
5,364,142
8,757,176
1,106,980
1,223,770
1,078,770
10,226,801
16,600,000
15,590,000
15,590,000
18,390,000
18,390,000
18,390,000
18,390,000
18,590,000
18,590,000
19,500,000
20,500,000
20,500,000
20,500,000
21,500,000
22,500,000
21,500,000
0
0
0
0
000021,500,00022,500,00021,500,00020,500,00020,500,00020,500,00019,500,00018,590,00018,590,00018,390,00018,390,00018,390,00018,390,00015,590,00015,590,00016,600,00010,226,8011,078,7701,223,7701,106,9808,757,1765,364,14217,837,77925,991,71048,066,41800000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48,066,418
25,991,710
17,837,779
5,364,142
8,757,176
1,106,980
1,223,770
1,078,770
10,226,801
876,090
731,090
0
0
0
0
0
0
0
0
0
0
0
34,641,195
36,026,763
35,031,050
35,031,050
40,262,474
35,698,448
0
035,698,44840,262,47435,031,05035,031,05036,026,76334,641,19500000000000731,090876,09010,226,8011,078,7701,223,7701,106,9808,757,1765,364,14217,837,77925,991,71048,066,41800000000000000000
       Accounts payable 
1,576,559
2,175,946
3,849,758
3,618,528
4,134,397
4,742,349
5,281,527
4,721,987
5,636,997
4,576,995
3,200,218
4,747,418
4,734,026
3,688,752
3,350,497
3,750,070
3,372,006
3,163,437
2,732,040
2,949,872
3,262,244
3,925,287
1,741,644
2,643,219
3,163,176
2,355,010
3,077,141
3,649,504
2,266,421
3,184,994
2,473,696
3,367,165
2,290,233
2,669,843
1,838,901
2,756,440
4,295,492
3,547,301
3,069,185
3,745,676
0
4,020,291
3,194,197
2,615,003
4,926,681
0
04,926,6812,615,0033,194,1974,020,29103,745,6763,069,1853,547,3014,295,4922,756,4401,838,9012,669,8432,290,2333,367,1652,473,6963,184,9942,266,4213,649,5043,077,1412,355,0103,163,1762,643,2191,741,6443,925,2873,262,2442,949,8722,732,0403,163,4373,372,0063,750,0703,350,4973,688,7524,734,0264,747,4183,200,2184,576,9955,636,9974,721,9875,281,5274,742,3494,134,3973,618,5283,849,7582,175,9461,576,559
       Other Current Liabilities 
2,203,632
8,172,145
6,033,224
5,704,333
6,701,849
2,355,749
3,580,306
2,334,176
2,578,313
1,918,063
2,801,930
3,875,959
2,579,714
1,838,941
1,675,694
1,453,004
1,143,993
1,658,440
1,059,274
1,699,018
1,932,217
1,958,625
1,992,802
2,922,222
2,340,075
3,570,890
2,644,629
2,332,687
1,810,804
1,982,700
2,131,293
2,752,483
2,053,864
2,382,365
2,077,313
2,213,427
2,071,041
2,614,602
1,771,518
75,625
575,385
68,596
47,833
46,091
49,989
0
049,98946,09147,83368,596575,38575,6251,771,5182,614,6022,071,0412,213,4272,077,3132,382,3652,053,8642,752,4832,131,2931,982,7001,810,8042,332,6872,644,6293,570,8902,340,0752,922,2221,992,8021,958,6251,932,2171,699,0181,059,2741,658,4401,143,9931,453,0041,675,6941,838,9412,579,7143,875,9592,801,9301,918,0632,578,3132,334,1763,580,3062,355,7496,701,8495,704,3336,033,2248,172,1452,203,632
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,056,483
5,053,362
7,013,276
22,349,749
6,354,408
6,313,783
8,077,673
8,077,6736,313,7836,354,40822,349,7497,013,2765,053,3625,056,483000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,503,905
16,117,002
16,287,092
4,368,743
4,263,850
2,733,249
2,761,387
13,137,925
13,327,414
13,036,164
13,352,122
2,039,774
1,935,776
3,315,461
3,312,340
5,272,254
0
0
0
0
00005,272,2543,312,3403,315,4611,935,7762,039,77413,352,12213,036,16413,327,41413,137,9252,761,3872,733,2494,263,8504,368,74316,287,09216,117,00215,503,90500000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-48,066,418
-25,991,710
-17,837,779
-5,364,142
-8,757,176
-1,106,980
-1,223,770
-1,078,770
-10,226,801
-16,600,000
-15,590,000
-15,590,000
-18,390,000
-18,390,000
-18,390,000
-18,390,000
-18,590,000
-18,590,000
-19,500,000
-20,500,000
-20,500,000
-20,500,000
-21,066,465
-22,036,135
-21,094,038
429,955
513,553
474,577
0
0474,577513,553429,955-21,094,038-22,036,135-21,066,465-20,500,000-20,500,000-20,500,000-19,500,000-18,590,000-18,590,000-18,390,000-18,390,000-18,390,000-18,390,000-15,590,000-15,590,000-16,600,000-10,226,801-1,078,770-1,223,770-1,106,980-8,757,176-5,364,142-17,837,779-25,991,710-48,066,41800000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
0
0
000-1000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,677,572
18,877,801
13,904,885
13,979,253
13,540,178
13,772,922
3,488,546
3,656,122
3,702,822
6,528,274
753,714
727,417
701,120
675,991
616,917
583,416
561,963
864,625
847,097
917,458
917,437
919,481
0
0
0
0
0
0
0
0000000919,481917,437917,458847,097864,625561,963583,416616,917675,991701,120727,417753,7146,528,2743,702,8223,656,1223,488,54613,772,92213,540,17813,979,25313,904,88518,877,80117,677,57200000000000000000
> Total Stockholder Equity
44,837,113
45,072,262
45,137,682
44,719,909
44,697,788
46,778,231
47,403,770
53,158,669
52,829,362
74,101,280
72,149,387
76,129,750
77,191,547
78,564,836
79,553,807
93,204,678
93,148,776
93,742,789
95,878,395
101,270,915
104,664,720
106,988,569
105,549,931
93,388,507
93,221,538
94,941,213
94,059,913
73,275,612
75,054,203
79,212,336
78,169,160
76,275,412
77,396,012
75,955,601
73,554,001
66,460,123
67,287,685
68,082,435
68,772,447
60,630,722
60,076,024
59,293,355
57,674,917
56,337,796
56,918,514
60,246,651
60,246,65156,918,51456,337,79657,674,91759,293,35560,076,02460,630,72268,772,44768,082,43567,287,68566,460,12373,554,00175,955,60177,396,01276,275,41278,169,16079,212,33675,054,20373,275,61294,059,91394,941,21393,221,53893,388,507105,549,931106,988,569104,664,720101,270,91595,878,39593,742,78993,148,77693,204,67879,553,80778,564,83677,191,54776,129,75072,149,38774,101,28052,829,36253,158,66947,403,77046,778,23144,697,78844,719,90945,137,68245,072,26244,837,113
   Common Stock
5,034,870
5,034,870
5,034,870
5,034,870
5,034,870
5,065,267
5,072,248
5,169,966
5,175,860
5,323,749
5,331,039
5,430,775
5,434,963
5,446,976
5,469,034
5,469,034
5,469,997
5,469,997
5,475,136
5,508,047
5,522,946
5,529,057
5,531,833
5,531,833
5,807,083
5,813,885
6,392,438
6,392,438
6,408,682
6,418,588
6,418,588
6,418,588
6,418,588
6,418,588
6,418,588
6,418,588
6,418,588
6,418,588
6,418,588
6,418,588
6,418,588
6,418,588
0
0
0
0
00006,418,5886,418,5886,418,5886,418,5886,418,5886,418,5886,418,5886,418,5886,418,5886,418,5886,418,5886,418,5886,418,5886,408,6826,392,4386,392,4385,813,8855,807,0835,531,8335,531,8335,529,0575,522,9465,508,0475,475,1365,469,9975,469,9975,469,0345,469,0345,446,9765,434,9635,430,7755,331,0395,323,7495,175,8605,169,9665,072,2485,065,2675,034,8705,034,8705,034,8705,034,8705,034,870
   Retained Earnings 
7,389,627
7,528,667
7,669,236
7,809,805
7,936,622
7,936,622
7,936,622
7,936,622
7,936,622
7,403,582
7,403,582
7,403,582
1,141,560
669,979
0
0
0
112,245
221,539
135,645
176,778
-6,119,437
-7,157,194
-18,654,852
-5,636,949
-5,875,413
-6,526,314
-27,018,048
-11,868,321
-10,913,643
-11,889,435
-13,831,018
-12,872,051
-13,742,318
-16,180,218
-18,290,373
-18,388,227
-17,281,913
-18,263,713
-24,804,163
-20,630,708
-21,357,160
-22,770,954
-23,783,265
-23,015,116
0
0-23,015,116-23,783,265-22,770,954-21,357,160-20,630,708-24,804,163-18,263,713-17,281,913-18,388,227-18,290,373-16,180,218-13,742,318-12,872,051-13,831,018-11,889,435-10,913,643-11,868,321-27,018,048-6,526,314-5,875,413-5,636,949-18,654,852-7,157,194-6,119,437176,778135,645221,539112,245000669,9791,141,5607,403,5827,403,5827,403,5827,936,6227,936,6227,936,6227,936,6227,936,6227,809,8057,669,2367,528,6677,389,627
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
86,429,949
86,210,549
82,679,410
84,674,288
85,131,220
85,131,220
85,131,220
84,573,007
84,573,007
79,538,679
79,538,679
79,538,679
80,686,811
81,010,643
76,010,643
76,010,643
0
0
0
0
000076,010,64376,010,64381,010,64380,686,81179,538,67979,538,67979,538,67984,573,00784,573,00785,131,22085,131,22085,131,22084,674,28882,679,41086,210,54986,429,94900000000000000000000000000
   Treasury Stock0000000000-989,457-989,457-989,457-989,457-989,457-989,457-989,457-989,457-989,457-989,457000-348,404-348,404-348,404-348,404-348,404-348,404-348,404-348,404-348,404-348,404-348,404-348,404-348,404-360,021-1,739,054-1,739,054-1,739,054-1,739,054-1,739,054-1,739,054-1,739,054-1,739,054-1,739,054
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
193,539
723,154
-425,076
-543,372
-412,366
-1,361,518
-1,053,139
-915,848
-576,932
8,334,705
-604,593
-1,050,269
-629,193
-375,913
-315,961
-97,741
-84,834
-267,919
513,977
1,439,395
1,127,831
1,887,868
-819,572
-574,611
-630,829
0
0
0
0
0000-630,829-574,611-819,5721,887,8681,127,8311,439,395513,977-267,919-84,834-97,741-315,961-375,913-629,193-1,050,269-604,5938,334,705-576,932-915,848-1,053,139-1,361,518-412,366-543,372-425,076723,154193,53900000000000000000



6.3. Balance Sheets

Currency in KRW. All numbers in thousands.




6.4. Cash Flows

Currency in KRW. All numbers in thousands.




6.5. Income Statements

Currency in KRW. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in KRW. All numbers in thousands.

Gross Profit (+$)
totalRevenue42,647,035
Cost of Revenue-29,988,868
Gross Profit12,658,16712,658,167
 
Operating Income (+$)
Gross Profit12,658,167
Operating Expense-48,920,122
Operating Income-6,273,088-36,261,956
 
Operating Expense (+$)
Research Development5,944,986
Selling General Administrative4,675,118
Selling And Marketing Expenses0
Operating Expense48,920,12210,620,104
 
Net Interest Income (+$)
Interest Income678,361
Interest Expense-2,551,945
Other Finance Cost-0
Net Interest Income-1,873,584
 
Pretax Income (+$)
Operating Income-6,273,088
Net Interest Income-1,873,584
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-5,739,453-6,273,088
EBIT - interestExpense = -2,551,945
-3,979,103
-1,427,158
Interest Expense2,551,945
Earnings Before Interest and Taxes (EBIT)0-3,187,508
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-5,739,453
Tax Provision-171,152
Net Income From Continuing Ops-5,910,605-5,910,605
Net Income-3,979,103
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net01,873,584
 

Technical Analysis of Komipharm
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Komipharm. The general trend of Komipharm is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Komipharm's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Komipharm International Co. Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 4,205 < 4,425 < 4,445.

The bearish price targets are: 3,910 > 3,770 > 3,735.

Tweet this
Komipharm International Co. Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Komipharm International Co. Ltd. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Komipharm International Co. Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Komipharm International Co. Ltd. The current macd is -73.11640327.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Komipharm price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Komipharm. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Komipharm price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Komipharm International Co. Ltd Daily Moving Average Convergence/Divergence (MACD) ChartKomipharm International Co. Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Komipharm International Co. Ltd. The current adx is 28.96.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Komipharm shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Komipharm International Co. Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Komipharm International Co. Ltd. The current sar is 4,218.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Komipharm International Co. Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Komipharm International Co. Ltd. The current rsi is 32.40. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Komipharm International Co. Ltd Daily Relative Strength Index (RSI) ChartKomipharm International Co. Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Komipharm International Co. Ltd. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Komipharm price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Komipharm International Co. Ltd Daily Stochastic Oscillator ChartKomipharm International Co. Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Komipharm International Co. Ltd. The current cci is -85.06224066.

Komipharm International Co. Ltd Daily Commodity Channel Index (CCI) ChartKomipharm International Co. Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Komipharm International Co. Ltd. The current cmo is -51.99010196.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Komipharm International Co. Ltd Daily Chande Momentum Oscillator (CMO) ChartKomipharm International Co. Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Komipharm International Co. Ltd. The current willr is -92.63157895.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Komipharm International Co. Ltd Daily Williams %R ChartKomipharm International Co. Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Komipharm International Co. Ltd.

Komipharm International Co. Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Komipharm International Co. Ltd. The current atr is 106.38.

Komipharm International Co. Ltd Daily Average True Range (ATR) ChartKomipharm International Co. Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Komipharm International Co. Ltd. The current obv is 1,551,299.

Komipharm International Co. Ltd Daily On-Balance Volume (OBV) ChartKomipharm International Co. Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Komipharm International Co. Ltd. The current mfi is 24.52.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Komipharm International Co. Ltd Daily Money Flow Index (MFI) ChartKomipharm International Co. Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Komipharm International Co. Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-07-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-07-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-18STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Komipharm International Co. Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Komipharm International Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.404
Ma 20Greater thanMa 504,142.000
Ma 50Greater thanMa 1004,135.200
Ma 100Greater thanMa 2004,120.050
OpenGreater thanClose3,975.000
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Komipharm with someone you think should read this too:
  • Are you bullish or bearish on Komipharm? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Komipharm? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Komipharm International Co. Ltd

I send you an email if I find something interesting about Komipharm International Co. Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Komipharm International Co. Ltd.

Receive notifications about Komipharm International Co. Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.